Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.56 |
| ▸ | DRD1 | P21728 | 9/20 | 0.56 |
| ▸ | DRD3 | P35462 | 8/20 | 0.56 |
| ▸ | DRD5 | P21918 | 8/20 | 0.56 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.55 |
| ▸ | BAD | Q92934 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPN | P05981 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7918691 | 0.85 | DRD2 (0.61) | DRD2DRD1DRD3DRD5BCL2L1 | |
| SCHEMBL31634362 | 0.85 | DRD2 (0.61) | DRD2DRD1DRD3DRD5BCL2L1 | |
| SCHEMBL29414699 | 0.84 | — | — | |
| SCHEMBL150017 | 0.84 | — | — | |
| SCHEMBL6905223 | 0.80 | BCL2L1 (0.54) | DRD2DRD1DRD3DRD5BCL2L1 | |
| Formaldehyde SCHEMBL17491106 | 0.78 | BCL2L1 (0.65) | DRD2DRD1DRD3DRD5BCL2L1 | |
| SCHEMBL31379414 | 0.78 | CYP2A6 (0.46) | DRD2DRD1DRD3DRD5DRD4 | |
| SCHEMBL266203 | 0.78 | BCL2L1 (0.53) | DRD2DRD1DRD3DRD5BCL2L1 | |
| SCHEMBL250734 | 0.76 | CYP2A6 (0.65) | DRD2DRD1DRD3DRD5DRD4 | |
| SCHEMBL7527997 | 0.76 | DRD2 (0.49) | DRD2DRD1DRD3DRD5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118791533-A | Compound and preparation method thereof, and preparation method of polyolefin elastomer | 中国科学院长春应用化学研究所 | 2024-10-18 | — | — | CN | claimed |
| CN-111909196-A | IVB group-containing bimetallic complex catalyst and preparation method and application thereof | 万华化学集团股份有限公司 | 2020-11-10 | — | — | CN | claimed |
| WO-2012104262-A1 | PHOTORESPONSIVE MICROCAPSULES AND COMPOSITIONS CONTAINING SAME | UNIVERSIDAD DE SEVILLA (ES) | 2012-08-09 | — | — | WO | claimed |
| EP-2467122-A2 | PHOTORESPONSIVE SUNSCREEN COMPOSITION | Blueshift Pharma GmbH (CH) | 2012-06-27 | — | — | EP | claimed |
| US-20120148647-A1 | Photoresponsive Sunscreen Composition | BLUESHIFT PHARMA GMBH (CH) | 2012-06-14 | — | — | US | claimed |
| WO-2011020928-A2 | PHOTORESPONSIVE SUNSCREEN COMPOSITION | BLUESHIFT PHARMA GMBH (CH) | 2011-02-24 | — | — | WO | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-6797745-B1 | Hot melt inks containing styrene or terpene polymers | XEROX CORPORATION | 2004-09-28 | — | — | US | claimed |
| US-5663030-A | A PHENYL OR NORBORNANE DERIVATIVE AS AN ADDITIVE TO REDUCE HEAT AND ENERGY REQUIRED TO FUSE THE TONER AND TO REDUCE JAMMING OF THE EQUIPMENT | XEROX CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| EP-0677076-B1 | DIARYL CARBINOL METATHESIS CATALYSTS | SHELL OIL CO (US) | 1997-04-16 | — | — | EP | claimed |
| EP-0677076-A1 | DIARYL CARBINOL METATHESIS CATALYSTS. | SHELL OIL CO (US) | 1995-10-18 | — | — | EP | claimed |
| WO-1994015989-A1 | DIARYL CARBINOL METATHESIS CATALYSTS | SHELL OIL COMPANY (US) | 1994-07-21 | — | — | WO | claimed |
| US-5276118-A | Metal complex | SHELL OIL COMPANY (US) | 1994-01-04 | — | — | US | claimed |
| EP-3400233-B1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | POP TEST ONCOLOGY LLC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12263178-B2 | Pharmaceutical compositions and methods | POP TEST ONCOLOGY LLC (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240358718-A1 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS | CORCEPT THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| US-4758639-A | Process for production of vinyl polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148647-A1 | Photoresponsive Sunscreen Composition | SUN2, MC1R, MITF | DRD2 3593/4885DRD1 3004/4885DRD3 3624/4885 |
| US-20240358718-A1 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATORS AND CYP3A INHIBITORS | NR3C1, NR3C2, CYP3A5 | DRD2 2195/4885DRD1 1883/4885DRD3 1639/4885 |
| US-12263178-B2 | Pharmaceutical compositions and methods | NR3C2, NR3C1, MC2R | DRD2 3609/4885DRD1 4220/4885DRD3 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.